Esperion therapeutics, inc. (ESPR)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Dec'12
Assets
Current assets:
Cash and cash equivalents

149,386

166,130

211,978

274,344

174,836

36,973

26,755

24,380

30,823

34,468

21,024

20,373

19,867

38,165

47,140

48,768

37,207

77,336

80,824

129,787

208,641

85,038

40,232

47,944

48,638

56,537

71,895

16,626

6,511

Restricted cash

928

928

928

928

1,193

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Short-term investments

7,931

34,651

31,883

26,882

53,692

99,050

132,463

155,793

166,400

165,731

182,347

147,035

162,017

173,418

162,961

158,410

157,263

134,925

134,772

94,995

69,467

20,803

12,729

11,780

8,064

3,525

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,449

-

Prepaid clinical development costs

1,189

6,081

5,653

3,977

4,392

5,275

7,411

7,650

2,864

2,072

1,630

2,554

4,786

560

1,732

1,121

1,430

888

1,963

550

1,053

366

894

1,330

1,257

196

503

212

367

Inventories

1,841

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other prepaid and current assets

11,354

3,924

2,758

792

923

1,334

1,581

1,060

1,321

1,653

1,822

986

1,343

1,434

1,634

789

1,154

1,245

1,286

381

665

492

724

265

320

362

535

70

259

Assets held for sale

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29

29

-

Total current assets

172,629

211,714

253,460

307,121

235,221

142,632

168,210

188,883

201,408

203,924

206,823

170,948

188,013

213,577

213,467

209,088

197,054

214,394

218,845

225,713

279,826

106,699

54,579

61,319

58,279

60,620

72,964

19,389

7,138

Property and equipment, net

1,447

1,145

958

903

439

520

583

311

374

435

497

558

623

674

622

685

743

807

722

680

728

780

840

851

360

81

78

89

120

Intangible assets

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

56

55

55

53

Right of use operating lease assets

5,510

1,532

260

198

185

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term investments

-

-

-

-

-

243

5,181

21,631

42,350

73,420

105,717

13,680

25,920

30,906

49,646

67,637

88,183

80,315

86,771

89,509

44,611

35,741

5,055

7,061

11,528

17,537

13,477

-

-

Right of use operating lease assets

-

-

796

734

766

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total assets

179,642

214,447

255,270

308,814

236,482

143,451

174,030

210,881

244,188

277,835

313,093

185,242

214,612

245,213

263,791

277,466

286,036

295,572

306,394

315,958

325,221

143,276

60,530

69,287

70,223

78,294

86,575

19,534

7,312

Liabilities and stockholders' equity
Current liabilities:
Short term borrowings with related parties, net of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,241

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

738

Accounts payable

15,114

28,856

23,735

28,404

33,270

44,893

18,630

22,482

11,962

20,375

19,503

18,714

11,636

4,595

1,783

1,566

1,540

707

1,979

3,305

2,899

2,040

3,299

4,211

2,098

2,232

1,944

1,655

476

Current portion of long-term debt

-

-

-

-

-

-

-

152

603

1,045

1,479

1,764

1,737

1,709

1,682

1,656

1,629

1,604

1,578

1,427

1,030

638

253

-

-

-

-

-

-

Accrued clinical development costs

22,687

17,511

20,954

17,301

18,871

16,039

20,030

9,524

15,440

10,506

11,000

8,264

6,371

8,138

2,447

2,505

1,401

2,191

963

1,015

1,958

1,978

929

360

526

884

449

923

242

Other accrued liabilities

23,570

11,871

9,944

4,809

3,774

3,401

3,625

2,806

2,043

1,218

3,015

2,253

1,861

1,147

2,248

1,908

1,423

1,123

2,308

1,282

1,052

835

1,150

885

564

1,087

948

1,212

210

Warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,852

265

Revenue interest liability

8,999

5,236

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue from collaborations

1,170

2,152

2,618

3,599

3,926

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

1,913

454

267

199

184

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

73,453

66,080

57,518

54,312

60,025

64,333

42,285

34,964

30,048

33,144

34,997

30,995

21,605

15,589

8,160

7,635

5,993

5,625

6,828

7,029

6,939

5,491

5,631

5,456

3,188

4,203

3,342

6,644

17,173

Revenue interest liability

152,716

127,308

128,420

124,409

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue from collaborations

-

-

-

-

655

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

3,719

1,109

820

759

792

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long term debt, net of discount

-

-

-

-

-

-

-

-

-

-

-

140

585

1,022

1,451

1,871

2,283

2,688

3,084

3,473

3,855

4,231

4,676

4,922

-

-

-

-

7,528

Total liabilities

229,888

194,497

186,758

179,480

61,472

64,333

42,285

34,964

30,048

33,144

34,997

31,135

22,190

16,611

9,611

9,506

8,276

8,313

9,912

10,502

10,794

9,722

10,307

10,378

3,188

4,203

3,342

6,644

24,702

Commitments and contingencies (Note 5)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

-

-

-

0

-

-

-

0

0

0

0

0

0

-

0

Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

Common stock, $0.001 par value; 120,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 27,548,133 shares issued and outstanding at March 31, 2020 and 27,497,911 shares issued and outstanding at December 31, 2019

28

27

27

27

27

27

27

27

27

26

26

23

23

23

23

23

23

23

23

22

22

20

15

15

15

15

15

0

0

Additional paid-in capital

723,232

715,166

701,794

694,266

685,816

677,511

670,340

664,817

657,497

641,801

636,821

467,504

462,471

457,951

454,379

450,661

446,529

441,940

437,548

433,793

430,348

238,031

145,187

144,064

142,954

142,142

141,585

796

609

Accumulated other comprehensive income

9

23

11

-16

-111

-319

-560

-776

-963

-845

-351

-239

-228

-172

22

118

15

-482

11

-60

-39

-59

2

5

3

-3

5

-

-

Accumulated deficit

-773,515

-695,266

-633,320

-564,943

-510,722

-598,101

-538,062

-488,151

-442,421

-396,291

-358,400

-313,181

-269,844

-229,200

-200,244

-182,842

-168,807

-154,222

-141,100

-128,299

-115,904

-104,438

-94,981

-85,175

75,937

-68,063

58,373

53,135

41,975

Total stockholders' equity (deficit)

-50,246

19,950

68,512

129,334

175,010

79,118

131,745

175,917

214,140

244,691

278,096

154,107

192,422

228,602

254,180

267,960

277,760

287,259

296,482

305,456

314,427

133,554

50,223

58,909

67,035

74,091

83,232

-52,338

-41,364

Total liabilities and stockholders' equity

179,642

214,447

255,270

308,814

236,482

143,451

174,030

210,881

244,188

277,835

313,093

185,242

214,612

245,213

263,791

277,466

286,036

295,572

306,394

315,958

325,221

143,276

60,530

69,287

70,223

78,294

86,575

19,534

7,312